SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-024322
Filing Date
2020-02-24
Accepted
2020-02-24 17:11:24
Documents
13
Period of Report
2020-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2010761d1_8k.htm 8-K 36077
2 EXHIBIT 4.1 tm2010761d1_ex4-1.htm EX-4.1 105683
3 EXHIBIT 4.2 tm2010761d1_ex4-2.htm EX-4.2 98825
4 EXHIBIT 4.3 tm2010761d1_ex4-3.htm EX-4.3 112052
5 EXHIBIT 5.1 tm2010761d1_ex5-1.htm EX-5.1 8431
6 EXHIBIT 10.1 tm2010761d1_ex10-1.htm EX-10.1 225377
7 EXHIBIT 10.2 tm2010761d1_ex10-2.htm EX-10.2 201775
8 EXHIBIT 10.3 tm2010761d1_ex10-3.htm EX-10.3 56089
9 EXHIBIT 10.4 tm2010761d1_ex10-4.htm EX-10.4 38119
10 EXHIBIT 99.1 tm2010761d1_ex99-1.htm EX-99.1 14228
11 GRAPHIC image_002.jpg GRAPHIC 7832
12 GRAPHIC image_001.jpg GRAPHIC 2561
13 GRAPHIC image_003.jpg GRAPHIC 4109
  Complete submission text file 0001104659-20-024322.txt   918338
Mailing Address 7 CLARKE DRIVE CRANBURY NJ 08512
Business Address 7 CLARKE DRIVE CRANBURY NJ 08512 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 20645429
SIC: 2836 Biological Products, (No Diagnostic Substances)